Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/10/2025 | $25.00 | Buy | Needham |
| 12/16/2024 | Outperform | Macquarie | |
| 10/11/2024 | $23.00 | Overweight | KeyBanc Capital Markets |
| 5/30/2024 | $23.00 | Outperform | Robert W. Baird |
| 4/22/2024 | $25.00 | Buy | Citigroup |
| 3/6/2024 | $22.00 | Equal Weight | Barclays |
| 2/26/2024 | $33.00 → $25.00 | Buy | Jefferies |
| 2/22/2024 | $21.00 | Buy → Neutral | BofA Securities |
4 - Privia Health Group, Inc. (0001759655) (Issuer)
4 - Privia Health Group, Inc. (0001759655) (Issuer)
4 - Privia Health Group, Inc. (0001759655) (Issuer)
8-K - Privia Health Group, Inc. (0001759655) (Filer)
10-Q - Privia Health Group, Inc. (0001759655) (Filer)
8-K - Privia Health Group, Inc. (0001759655) (Filer)
Needham initiated coverage of Privia Health with a rating of Buy and set a new price target of $25.00
Macquarie initiated coverage of Privia Health with a rating of Outperform
KeyBanc Capital Markets initiated coverage of Privia Health with a rating of Overweight and set a new price target of $23.00
4 - Privia Health Group, Inc. (0001759655) (Issuer)
3 - Privia Health Group, Inc. (0001759655) (Issuer)
4 - Privia Health Group, Inc. (0001759655) (Issuer)
ARLINGTON, Va., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) today announced that it expects to release financial results for its third-quarter and nine-month periods ended September 30, 2025 before market open on Thursday, November 6, 2025. The press release is expected to be publicly disseminated by 7:00 am ET and will also be available on the Company's Investor Relations website at ir.priviahealth.com. Privia Health management will host a conference call beginning at 8:00 am ET on the same day, Thursday, November 6, to discuss the results and management's outlook for future financial and operational performance. You can visit ir.priviahealth.com/news-and-e
Transaction enhances focus on specialty condition management and accelerates Evolent's deleveraging path.Proceeds from the transaction to be used to prepay senior term debt; Immediately accretive to Evolent's free cash flow by more than $7 million per year.Evolent reiterates outlook for Q3 2025 and full year 2025 for Revenue and Adjusted EBITDA, excluding the effect of the transaction.WASHINGTON, Sept. 23, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent"), a company focused on achieving better health outcomes for people with complex conditions, today announced that it has agreed to sell its value-based primary care business, Evolent Care Partners ("ECP"), to Privia Health Grou
ARLINGTON, Va., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) announced that it signed a definitive agreement to acquire an Accountable Care Organization (ACO) business from Evolent Health, Inc. (NYSE:EVH). The ACO business cares for over 120,000 attributed lives through the Medicare Shared Savings Program (MSSP), as well as various commercial and Medicare Advantage programs. With this transaction, Privia Health will now serve approximately 1.5 million attributed lives in value-based care (VBC) arrangements across commercial, Medicare, Medicare Advantage and Medicaid. Privia Health will pay $100 million in cash at closing and up to an additional $13 million su
ARLINGTON, Va., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) announced that it signed a definitive agreement to acquire an Accountable Care Organization (ACO) business from Evolent Health, Inc. (NYSE:EVH). The ACO business cares for over 120,000 attributed lives through the Medicare Shared Savings Program (MSSP), as well as various commercial and Medicare Advantage programs. With this transaction, Privia Health will now serve approximately 1.5 million attributed lives in value-based care (VBC) arrangements across commercial, Medicare, Medicare Advantage and Medicaid. Privia Health will pay $100 million in cash at closing and up to an additional $13 million su
ARLINGTON, Va., July 08, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) announced the appointment of Lance V. Berberian to its Board of Directors, effective July 15, 2025. He has also been named a member of the Audit Committee of the Board. Following the appointment of Mr. Berberian, the Board will comprise 10 directors. "We are excited to welcome Lance to our Board of Directors," said David King, Chairman of the Board, Privia Health Group, Inc. "Lance brings extensive technology strategy and digital transformation experience to the Board, including IT governance, infrastructure management and cybersecurity. We believe his expertise will be invaluable to Privia Health as
ARLINGTON, Va., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) announced that Edward C. Fargis has been named Executive Vice President, General Counsel and Corporate Secretary, effective today. Mr. Fargis will serve as the Company's chief legal officer, working with Privia executive leadership to support the Company's long-term direction and growth. "Ed is a proven leader who brings an invaluable healthcare industry perspective as well as extensive experience managing corporate governance, compliance and strategic transactions," said Parth Mehrotra, CEO, Privia Health. "As Privia continues to grow and our industry evolves, we are fortunate to have Ed joining us
ARLINGTON, Va., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) today announced that it expects to release financial results for its third-quarter and nine-month periods ended September 30, 2025 before market open on Thursday, November 6, 2025. The press release is expected to be publicly disseminated by 7:00 am ET and will also be available on the Company's Investor Relations website at ir.priviahealth.com. Privia Health management will host a conference call beginning at 8:00 am ET on the same day, Thursday, November 6, to discuss the results and management's outlook for future financial and operational performance. You can visit ir.priviahealth.com/news-and-e
Transaction enhances focus on specialty condition management and accelerates Evolent's deleveraging path.Proceeds from the transaction to be used to prepay senior term debt; Immediately accretive to Evolent's free cash flow by more than $7 million per year.Evolent reiterates outlook for Q3 2025 and full year 2025 for Revenue and Adjusted EBITDA, excluding the effect of the transaction.WASHINGTON, Sept. 23, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent"), a company focused on achieving better health outcomes for people with complex conditions, today announced that it has agreed to sell its value-based primary care business, Evolent Care Partners ("ECP"), to Privia Health Grou
Very Strong First Half Performance Across All Key Operating and Financial MetricsImplemented Providers +13.8% and Practice Collections +18.5% compared to 2Q'24Guidance Raised to Above High End of Range for Practice Collections, GAAP Revenue, Platform Contribution and Adjusted EBITDA c ARLINGTON, Va., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) today announced financial results for the second quarter ended June 30, 2025. Second Quarter Performance For the Three Months Ended June 30, ($ in millions, except per share amounts) 2025 2024 Change (%) Total revenue $521.2 $422.3 23.4%Gross profit $112.8 $98.3 14.8%Operating income $3.3 $5.1 (34.6)%Ne
SC 13G/A - Privia Health Group, Inc. (0001759655) (Subject)
SC 13G/A - Privia Health Group, Inc. (0001759655) (Subject)
SC 13G/A - Privia Health Group, Inc. (0001759655) (Subject)